Seoul National University Hospital
snuh.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,881
Active
234
Phase 3
86
Total enrollment
6,604,124
Pipeline matrix
Showing 40 of 98 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexamethasone | — | — | — | 6 | |||
| Crystalloid solutions | — | — | — | — | 2 | ||
| Prednisolone | — | — | — | — | — | 4 | |
| Febuxostat | — | — | — | — | 2 | ||
| Lidocaine | — | — | — | — | — | 2 | |
| Fentanyl-Morphine | — | — | — | — | — | 1 | |
| Volulyte® | — | — | — | — | — | 1 | |
| Acetaminophen/Ibuprofen | — | — | — | — | — | 1 | |
| Clopidogrel treatment group | — | — | — | — | — | 1 | |
| Dual antiplatelet agent duration | — | — | — | — | — | 1 | |
| Antiplatelet Drug | — | — | — | — | — | 1 | |
| EPHEDrine Hydrochloride 5 mg/ml | — | — | — | — | — | 1 | |
| Livact Granule | — | — | — | — | — | 1 | |
| Phenoxybenzamine | — | — | — | — | — | 1 | |
| Eleveld model-guided dosing | — | — | — | — | — | 1 | |
| Standard weight-based label dosing | — | — | — | — | — | 1 | |
| Remifentanil (Limited) - Target Controlled Infusion system | — | — | — | — | — | 1 | |
| Remifentanil (Control) - Target Controlled Infusion system | — | — | — | — | — | 1 | |
| Saline | — | — | 6 | ||||
| Morphine | — | — | — | — | 3 | ||
| Acetaminophen | — | — | — | — | 3 | ||
| Warfarin | — | — | — | — | 3 | ||
| Rifampicin | — | — | — | 4 | |||
| Ethambutol | — | — | — | — | 2 | ||
| Pyrazinamide | — | — | — | — | 2 | ||
| Fecal microbiota transplantation | — | — | — | — | — | 1 | |
| High-dose rifampicin | — | — | — | — | — | 1 | |
| MDR-END Plus regimen | — | — | — | — | — | 1 | |
| Standard-of-care (SoC) treatment | — | — | — | — | — | 1 | |
| Folfirinox | — | — | — | — | — | 1 | |
| mFOLFIRINOX-FOLFIRI intensified chemotherapy | — | — | — | — | — | 1 | |
| FOLFOX or CAPOX adjuvant chemotherapy | — | — | — | — | — | 1 | |
| Isoniazid | — | — | — | — | 2 | ||
| Olaparib | — | — | — | — | — | 3 | |
| SNUH-CD19-CAR-T | — | — | — | — | 2 | ||
| Durvalumab | — | — | — | — | — | 5 | |
| Bortezomib | — | — | — | — | — | 2 | |
| Tislelizumab | — | — | — | — | — | 2 | |
| Golcadomide + Poseltinib + Rituximab | — | — | — | — | — | 1 | |
| Tamoxifen Oral Product | — | — | — | — | — | 1 |
58 more active programs hidden
Next readouts
- 2022-03-04
- 2022-10-01
- 2022-12-22
- 2023-07-19
- 2023-10-31
- 2024-05-15
- 2024-12
- 2024-12-31
- 2024-12-31
- 2025-01-15
Top conditions
- Coronary Artery Disease41
- Hepatocellular Carcinoma39
- Healthy25
- Breast Cancer23
- Anesthesia17
- Anesthesia, General17
- Schizophrenia16
- Pancreatic Cancer16
Frequently asked questions about Seoul National University Hospital
- How many clinical trials does Seoul National University Hospital have on ClinicalTrials.gov?
- Seoul National University Hospital is listed as the lead sponsor on 1,881 clinical trials in ClinicalTrials.gov, 234 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Seoul National University Hospital's trials are in Phase 3?
- 86 of Seoul National University Hospital's trials are in Phase 3, spread across 98 active drug programs.
- What therapeutic areas does Seoul National University Hospital focus on?
- Seoul National University Hospital's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Hepatocellular Carcinoma, Healthy, Breast Cancer, Anesthesia.
- When are Seoul National University Hospital's next clinical trial readouts?
- Seoul National University Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Efficacy and Safety of Apixaban in Korean Frail Atrial Fibrillation Patient”, expected around 2022-03-04.